Clone:
REAL822
Type of antibody:
Releasable fluorochromes, Primary antibodies, Recombinant antibodies
Applications:
MICS, IHC, IF
Alternative names:
CK19, KRT19, Keratin 19, CK-19

Specifications for Cytokeratin 19 Antibody, anti-human, REAdye_lease™

Overview

Clone REAL822 is an antibody fragment derived from the full Cytokeratin 19 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL822 recognizes the human Cytokeratin 19, a type I cytokeratin of the keratin family which consists of intermediate filament proteins. They are responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. Cytokeratin 19 is the smallest human cytokeratin and is expressed in a large number of epithelial cell types, including many ductal and glandular epithelia.
Cytokeratin 19 has been specified as a marker of tissue differentiation and can be used in the detection of a variety of tumors.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).

Alternative names

CK19, KRT19, Keratin 19, CK-19

Detailed product information

Technical specifications

CloneREAL822
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable fluorochromes, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCytokeratin 19
Alternative names of antigenCK19, KRT19, Keratin 19, CK-19
Distribution of antigenepithelial cells, pancreas, muscle, intestine
RRIDAB_2857769

References for Cytokeratin 19 Antibody, anti-human, REAdye_lease™

Publications

  1. Gao, J. et al. (2014) Serum cytokeratin 19 fragment, CK19-2G2, as a newly identified biomarker for lung cancer. PLoS One 9(7): e101979
  2. Saha, S. K. et al. (2018) Cytokeratin 19 (KRT19) has a Role in the Reprogramming of Cancer Stem Cell-Like Cells to Less Aggressive and More Drug-Sensitive Cells. Int J Mol Sci 19(5)